For the first time, Australian ROS1+ lung cancer patients may have affordable access to Entrectnib. Currently, ROS1 patients cannot get access to Entrectnib outside of a clinical trial. We need the help of ROS1ders to make it happen. From 1 February 2020, Australian who have ROS1+ lung cancer may be able to purchase the medication … Continue reading Calling all ROS1ders! Please help Australians access Entrectinib
Lung Cancer Canada (LCC) is seeking ROS1 positive non-small cell lung cancer (NSCLC) patients and caregivers who have past or present treatment experience with ENTRECTINIB to share their experiences. This information will be used to provide patient/caregiver input that will help in determining accessibility of this drug for lung cancer patients in Canada. LCC and … Continue reading ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!
Yesterday the FDA has granted Priority Review for entrectinib for the treatment of ROS1-positive NSCLC and NTRK fusion-positive solid tumors. The FDA is expected to make a decision on approval by August 18, 2019. FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
Holy rash almighty. Below is a graphic image for mature audiences only. Consider yourself warned. …continue reading…